HDAC9 and rhabdomyosarcoma: Transcriptional architecture of rhabdomyosarcoma requires the balanced status of histone modification [37]. The utility of epigenetic modifiers and chromatin remodelers such as histone deacetylase (HDAC) inhibitors and bromodomain and extraterminal domain (BET) protein inhibitor, respectively, are under investigation [38, 39]. Genomic landscape has been proven in RMS.